Oral antidiabetic drugs and GLP-1 analogues in the treatment of type 2 diabetes – Related resources
02.06.2016 • Sonuncu dəyişiklik 27.08.2008
This article is created and updated by the EBMG Editorial Team
Cochrane reviews
- Glucagon-like peptide analogues (exanatide or liraglutide), in combination with metformin or sulphonylurea or both, are effective in improving glycaemic control in patients with type 2 diabetes. Alpha-glucosidase inhibitors have a significant effect on glycemic control and insulin levels, but no statistically significant effect on lipids and body weight. It is unclear whether alpha-glucosidase inhibitors influence mortality or morbidity in patients with type 2 diabetes .
- Rosiglitazone is not effective in improving patient-oriented outcomes such as mortality, morbidity, costs and health-related quality of life for type 2 diabetes mellitus. It appears to increase the occurrence of oedema and the risk of myocardial infarction .
- The use of DPP-4 inhibitors appears to result in a slight improvement in glycaemic control compared to placebo, but there are no data on patient-oriended outcomes such as health-related quality of life, diabetic complications and all-cause mortality, and there is insufficient evidence on the effectiveness of DPP-4 inhibitors as add-on drugs .
Other evidence summaries
- Metformin lowers blood glucose as effectively as sulfonylureas, with the advantage of better weight control .
- Acarbose may be a reasonable choice as adjunct therapy for patients with poorly controlled NIDDM .
- Incretin-based therapy with GLP-1 analogues or DPP4 inhibitors in adults with type 2 diabetes is moderately effective in improving glycaemic control, with greater reductions in postprandial glycaemia and favourable (GLP-1 analogues) or neutral (DPP4 inhibitors) effects on weight. Long-term efficacy and safety are under surveillance .
Literature
Clinical practice reviews
- Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010 Jun 26;375(9733):2234-43.
Other literature
- Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008 Apr;155(4):712-7.